SCHEMBL25864281

SCHEMBL25864281

O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)c(O)c2)C12CCCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.54
HSD17B10 Q99714 6/20 0.54
MAPT P10636 6/20 0.54
RECQL P46063 5/20 0.54
KDM4E B2RXH2 5/20 0.54
CYP19A1 P11511 5/20 0.54
CYP1A2 P05177 4/20 0.54
POLB P06746 4/20 0.54
GAA P10253 4/20 0.54
ALOX15 P16050 3/20 0.54
MAPK1 P28482 3/20 0.54
CA12 O43570 3/20 0.54
CYP1A1 P04798 3/20 0.54
CA4 P22748 3/20 0.54
CYP2C19 P33261 3/20 0.54
CA7 P43166 3/20 0.54
CYP1B1 Q16678 3/20 0.54
ALDH1A1 P00352 3/20 0.54
PKM P14618 3/20 0.54
HPGD P15428 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15544677 0.82 RECQL (0.55) CYP3A4HSD17B10MAPTRECQLKDM4E
SCHEMBL31237635 0.82 RECQL (0.55) CYP3A4HSD17B10MAPTRECQLKDM4E
SCHEMBL28763278 0.81 CYP1A2 (0.51) CYP3A4HSD17B10MAPTRECQLKDM4E
SCHEMBL6068882 0.71 CYP3A4 (0.53) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL23686074 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL29709569 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL29382523 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL19180 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL30468822 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E
Eriodictyol SCHEMBL29603762 0.70 CYP19A1 (1.00) CYP3A4HSD17B10MAPTRECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233513-A1 TAXIFOLIN FORMULATION COMPRISING THIAMINE EVANIUM HEALTHCARE GMBH (DE) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233513-A1 TAXIFOLIN FORMULATION COMPRISING THIAMINE SLC19A2, TTPA, FPGS CYP3A4 1472/4885HSD17B10 2981/4885MAPT 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.